Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Seer ( (SEER) ) has provided an announcement.
On March 30, 2026, Seer, Inc. reported that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board issued a March 23, 2026 Final Written Decision in an inter partes review of U.S. Patent No. 11,435,360, which underpins its Proteograph platform. The review, initiated by Bruker subsidiaries PreOmics and Biognosys, challenged 11 of 29 claims, and the board ultimately left 23 claims in force, including five challenged and 18 unchallenged claims.
The surviving claims cover key aspects of Seer’s nano- and microparticle protein enrichment methods, including depth and dynamic range of protein detection and particle-related features, thereby preserving legal protection for core elements of the Proteograph Product Suite. Management framed the outcome as validation of the strength of Seer’s intellectual property and its technology platform, reinforcing the company’s competitive position in deep proteomics as it continues to defend and invest in its patent estate.
The most recent analyst rating on (SEER) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Seer stock, see the SEER Stock Forecast page.
Spark’s Take on SEER Stock
According to Spark, TipRanks’ AI Analyst, SEER is a Neutral.
The score is held back primarily by persistent operating and free-cash-flow losses (despite improvement) and a bearish technical setup with the stock below key moving averages. Offsetting factors include low leverage, improving margins and cash-burn trajectory, and an earnings-call outlook that balances conservative near-term revenue guidance with strong operational milestones and a solid cash runway.
To see Spark’s full report on SEER stock, click here.
More about Seer
Seer, Inc., based in Redwood City, Calif., is a proteomics company focused on delivering deep, unbiased proteomic insights for research use. Its Proteograph Product Suite combines proprietary engineered nanoparticles, automation instrumentation, optimized consumables, and analytical software to enable scalable, high-precision analysis of proteins in biological samples for non-diagnostic applications.
The company’s technology is protected by an extensive intellectual property portfolio comprising more than 240 issued and pending patents worldwide, including 80 issued patents. Seer positions itself as a standard-setter in advanced proteomic workflows, targeting customers that require high-throughput, reproducible protein analysis across a wide dynamic range.
Average Trading Volume: 270,608
Technical Sentiment Signal: Sell
Current Market Cap: $93.66M
See more insights into SEER stock on TipRanks’ Stock Analysis page.